Vision-MR Ablation Catheter 2.0
DeviceCatheter ablation of ventricular tachycardia
NCT Number: NCT05543798
The VISABL-VT is a prospective, single-arm, multi-center, interventional investigation of the safety and efficacy of radiofrequency (RF) ablation of ventricular tachycardia associated with ischemic cardiomyopathy performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Herzzentrum Leipzig, Leipzig, Saxony, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Catheter ablation of ventricular tachycardia
Time frame: Perioperative/Periprocedural
Absence of inducible clinical ventricular tachycardia (VT) following the last RF application with with the Vision-MR Ablation Catheter 2.0
Time frame: 7 days
Composite of any procedure or device related serious adverse events through 7 days post index ablation procedure
Time frame: 6 months
Chronic success defined as 6-month freedom from recurrence of sustained VT or VT requiring intervention and freedom from new or increased dose of Class I or III antiarrhythmic drugs (AAD) at 6 months following the index ablation procedure.
Contact information is provided by the study sponsor or research team.
Imricor Medical Systems
Industry
Vision-MR Ablation Catheter 2.0 for the Treatment of Ventricular Tachycardia
Acronym: VISABL-VT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05511246
Arrhythmias, Cardiac, Cardiac Conduction System Disease
Houston, Texas, United States
View Trial DetailsNCT07324031
Arrhythmias, Cardiac, Cardiac Conduction System Disease
Scottsdale, Arizona, United States
View Trial DetailsNCT06281977
Arrhythmias, Cardiac, Cardiac Conduction System Disease
Rochester, Minnesota, United States
View Trial DetailsNCT07116525
Arrhythmias, Cardiac, Atrial Fibrillation
Bruges, Belgium
View Trial Details